Fiscal Year 2016 Press conference | February 22, 2017

Rice Powell - CEO Mike Brosnan - CFO

Fresenius Medical Care – global footprint in 2016

© | Press Conference | FY 2016 2

Every 0.7 seconds we provide a dialysis treatment

> 3,600

Clinics +6%

> 308,000

Patients +5%

> 109,000

Employees +5%

> 46.5million

Treatments +4%

2015 2016 2015 2016

Revenue in $m

EBIT in $m

Net income1

in $m

+7%

+13% +21%

2016 – Record year

2015 2016

16,738 17,911

Ambitious growth targets achieved

Very good performance in North America

Care Coordination again with significant top-line growth

Proposed dividend increase of 20% for fiscal 2016

2,327 2,638

1,029 1,243

3 © | Press Conference | FY 2016

1 Net income attr. to shareholders of FME

2016 – revenue breakdown North America US$ million

Revenue 12,886 +9%

Organic growth +7%

EMEA US$ million

Revenue 2,667 +1%

Organic growth +2%

Latin America US$ million

Revenue 712 -7%

Organic growth +17%

Asia-Pacific US$ million

Revenue 1,632 +9%

Organic growth +8%

72% North America

15% EMEA

9% Asia-Pacific

4% Latin America

US$m 17,911

+7%

4 © | Press Conference | FY 2016

Dialysis services Dialysis products

Therapies & laboratory services for patients with

chronic kidney failure

Care Coordination

North America - Businesses

supporting dialysis, e.g. vascular services

e.g., dialysis machines, dialyzers &

bloodline systems

Health care services Products

19% 13% 68%

Our solid revenue profile Percentage of FY 2016 revenue (US$)

12.2bn 2.3bn 3.4bn

5 © | Press Conference | FY 2016

FY 2016 US$ million

FY 2015 US$ million

Growth in %

Growth in %cc

Organic growth in %

Total Health Care 14,519 13,392 8 9 8

North America 11,982 10,932 10 10 8

of which CareCoordination 2,307 1,882 23 23 20

EMEA 1,294 1,226 6 9 3

Asia-Pacific 730 667 9 3 4

Latin America 513 567 (9) 15 20

Health Care Services - continued strong growth

cc = constant currency

Increased US organic revenue per treatment by US$ 5 to US$ 351

Growth in same market dialysis treatments by 3.2%

Care Coordination with ongoing significant organic growth

Contributions from acquisitions

1 North America 82%

2 EMEA 9%

3 Asia-Pacific 5%

4 Latin America 4% 1

4 3 2

US$m 14,519

+8%

6 © | Press Conference | FY 2016

Revenue

Stable Dialysis Products development FY 2016

US$ million FY 2015

US$ million Growth

in % Growth

in %cc

Total Dialysis Products 3,392 3,346 1 4

North America 904 881 3 3

EMEA 1,373 1,403 (2) --

Asia-Pacific 902 835 8 12

Latin America 199 199 -- 7

Corporate 14 28 (48) (48)

27%

73% Revenue growth in line with

global patient growth

Strong results in North America and Asia-Pacific segment

cc = constant currency

1 4

3

2

US$m 3,392

+1%

1 North America 27%

2 EMEA 40%

3 Asia-Pacific 27%

4 Latin America 6%

7 © | Press Conference | FY 2016

Products business - new generation of machines

8 © | Press Conference | FY 2016

Innovating for our patients

R&D 2016

Spend 162 US$ million (+16%) 5% of our product revenue 7,748 patents 794 employees, FTE (+22%)

6008 - new dialysis machine

Innovative and userfriendly Technologies for lower ramp up time,

faster cleaning, safer treatments Allow skilled nurses more time with

patients

20th consecutive dividend increase

Continuously delivering returns to shareholders

Dividend proposal in line with net income growth

0.77

2013

0.75

2012

0.80

2015

0.78

2014

0.96*

2016

Dividend per share in EUR

*proposed dividend for approval at the AGM on May 11, 2017

+20%

9 © | Press Conference | FY 2016

Changing health care systems C

omp

lexi

ty

Responsibility

Example: Reimbursement in the U.S. health care system

10 © | Press Conference | FY 2016

Recent M&A activities

Intensified focus on India as a key market in Asia Pacific

Dialysis Service segment backed by well established product business

Q3 2016 Q4 2016 H1 2017 (e) 1

Dialysis Care Coordination

11 © | Press Conference | FY 2016

Access to a unique product portfolio in the field of extracorporeal lung and heart assist

Lung support treatments similar to hemodialysis

Leverage FMEs core competence of operating outpatient facilities

Roll out Care Coordination services outside the US

New products 1 subject to closing, which is expected in H1 2017

Outlook1

Ambitious targets for revenue and net income growth

12 © | Press Conference | FY 2016

Guidance 2017 2016 base (IFRS/€m)

Revenue growth 8 to 10% 16,570

Net income2 growth 7 to 9% 1,144

1 Outlook based on constant currencies | 2 Net income attr. to shareholders of FME

• Continuous growth in our core business

• Enhancing both products and treatments

• Expanding Care Coordination business

• Increasing flexibility and efficiency

13 © | Press Conference | FY 2016

Vision 2020

(2014-2020, avg. % p.a.) 20202

(IFRS/€bn)

Revenue growth ~ 10 24

Net income growth high single digit

Outlook1

1 Outlook based on constant currencies | 2 US-GAAP US$ 28bn target translated to IFRS/€ with fx rates as of the beginning of 2017

Summary

14 © | Press Conference | FY 2016

We continuously improve the quality of life for our patients

We delivered on our targets of strong revenue and profit growth We delivered on our Global Efficiency Program savings

Progress in our Care Coordination business continues, we are

positioned as a provider of choice for value-based care in the US

© | Press Conference | FY 2016 15

Safe harbor statement: This presentation includes certain forward-looking statements within the

meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S.

Securities Act of 1934, as amended. The Company has based these forward-looking statements on current

estimates and assumptions made to the best of our knowledge. Actual results could differ materially from

those included in the forward-looking statements due to various risk factors and uncertainties, including

changes in business, economic competitive conditions, regulatory reforms, foreign exchange rate

fluctuations, uncertainties in litigation or investigative proceedings and the availability of financing. Given

these uncertainties, readers should not put undue reliance on any forward-looking statements. These and

other risks and uncertainties are discussed in detail in Fresenius Medical Care AG & Co. KGaA’s (FMC AG &

Co. KGaA) Annual Report on Form 20-F under the heading “Forward-Looking Statements” and under the

headings in that report referred to therein, and in FMC AG & Co. KGaA’s other reports filed with the

Securities and Exchange Commission (SEC) and the German Exchange Commission (Deutsche Börse).

Forward-looking statements represent estimates and assumptions only as of the date that they were made.

The information contained in this presentation is subject to change without notice and the company does

not undertake any duty to update the forward-looking statements, and the estimates and assumptions

associated with them, except to the extent required by applicable law and regulations.

If not mentioned differently the term net income after minorities refers to the net income attributable to

the shareholders of Fresenius Medical Care AG Co. KGaA. The term EMEA refers to the region Europe,

Middle East and Africa. Amounts are in US-$ if not mentioned otherwise.

Fiscal Year 2016 Press conference | February 22, 2017

Rice Powell - CEO Mike Brosnan - CFO